S1PR1 and glioblastoma: Thus, the purpose of this study was to discover the antitumoral efficiency of S1PR1 modulation in GBM cells by the agonist ACT-209905, which represents a ponesimod analogue that acts as a functional antagonist with immunomodulating properties, probably mechanistically, in a similar manner as ponesimod [31,32,33].